Our findings on reduced risks of anxiety or depression associated with GLP1-RA use were consistent with some previous findings (Bode et al., 2010; Grant et al., 2011; Idris et al., 2013; de Wit et al., 2014), but contrast with others that showed no significant association between GLP1-RA medication and depression (de Wit et al., 2016; O'Neil et al., 2017; Kahal et al., 2019). The gene discussed is GLP1R; the disease is depressive symptom measurement.